Market closedNon-fractional
CEL-SCI/CVM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About CEL-SCI
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company's core capabilities that include are drug discovery, research, development and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
Ticker
CVM
Sector
Healthcare
Trading on
AMEX
Industry
Biotechnology
Headquarters
Vienna, United States
Employees
44
Website
cel-sci.com
CEL-SCI Metrics
BasicAdvanced
$66M
Market cap
-
P/E ratio
-$0.63
EPS
1.04
Beta
-
Dividend rate
Price and volume
Market cap
$66M
Beta
1.04
Financial strength
Current ratio
1.673
Quick ratio
1.047
Long term debt to equity
73.623
Total debt to equity
88.303
Interest coverage (TTM)
-39.26%
Management effectiveness
Return on assets (TTM)
-53.51%
Return on equity (TTM)
-173.88%
Valuation
Price to book
4.59
Price to tangible book (TTM)
4.65
Price to free cash flow (TTM)
-2.838
Growth
Earnings per share change (TTM)
-23.30%
3-year earnings per share growth (CAGR)
-11.51%
What the Analysts think about CEL-SCI
Analyst Ratings
Majority rating from 1 analysts.
CEL-SCI Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q2 24
QoQ growth
Revenue
$0
NaN%
Net income
-$7.2M
7.46%
Profit margin
0.00%
NaN%
CEL-SCI Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q2 24
Q3 24
Actual
-$0.19
-$0.19
-$0.16
-$0.14
-
Expected
-$0.17
-$0.16
-$0.16
-$0.14
-$0.13
Surprise
11.76%
18.12%
0.00%
0.00%
-
CEL-SCI News
AllArticlesVideos
CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population
Business Wire·1 month ago
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer
Business Wire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for CEL-SCI stock?
CEL-SCI (CVM) has a market cap of $66M as of July 27, 2024.
What is the P/E ratio for CEL-SCI stock?
The price to earnings (P/E) ratio for CEL-SCI (CVM) stock is 0 as of July 27, 2024.
Does CEL-SCI stock pay dividends?
No, CEL-SCI (CVM) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next CEL-SCI dividend payment date?
CEL-SCI (CVM) stock does not pay dividends to its shareholders.
What is the beta indicator for CEL-SCI?
CEL-SCI (CVM) has a beta rating of 1.04. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell CEL-SCI stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.